INDP Indaptus Therapeutics, Inc.

Nasdaq indaptusrx.com


$ 3.59 $ 0.08 (2.25 %)    

Friday, 24-Oct-2025 15:59:51 EDT
QQQ $ 617.27 $ 6.52 (1.07 %)
DIA $ 472.05 $ 4.92 (1.05 %)
SPY $ 677.02 $ 5.49 (0.82 %)
TLT $ 91.31 $ 0.04 (0.04 %)
GLD $ 378.30 $ -1.27 (-0.34 %)
$ 3.63
$ 3.65
$ 3.37 x 10
$ 3.62 x 150
$ 3.53 - $ 3.72
$ 2.22 - $ 47.60
35,471
na
3.93M
$ 1.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of t...

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 indaptus-reports-partial-response-from-decoy20-monotherapy-in-urothelial-cancer-combo-with-pd-1-inhibitor-shows-favorable-safety

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastasesDecoy20 combination with PD-...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION